11% Of Americans Now Take GLP-1 Drugs—As Obesity Rate Declines, Poll Finds I cover breaking news.Jul 07, 2026, 08:57am EDTJul 07, 2026, 09:27am EDTToplineAbout one in nine Americans take a GLP-1 medication for weight loss, results from a new Gallup poll released on Tuesday found—a staggering rise over the past two years as the obesity rate in the U.S. continues to decline from a record high in 2022.A new Gallup poll found about 11% of Americans were taking a GLP-1 medication for weight loss.UCG/Universal Images Group via Getty ImagesKey FactsA record high 11% of Americans are taking a GLP-1 medication for weight loss, according to Gallup, up 3% from 2024.At the same time, Gallup points out the obesity rate among Americans fell to 36.4% in 2026, down from a record high of 39.9% in 2022, the year after GLP-1 medication Wegovy was first approved by the Food and Drug Administration to treat weight loss.The diabetes rate has also remained flat for the past few years, according to Gallup’s data.68% of GLP-1 users reported taking a name brand drug developed by pharmaceutical giants like Novo Nordisk and Eli Lilly, including Ozempic, Mounjaro or Zepbound, while 19% said they took custom-mixed drugs unapproved by the FDA.Public awareness of GLP-1 medications has also surged in recent years, with about 91% of respondents in 2026 reporting they knew the drugs could treat weight loss—up from 80% in 2024.This is a breaking story and will be updated.LOADING VIDEO PLAYER...FORBES’ FEATURED Video